The shares of GlaxoSmithKline Pharmaceuticals have rallied over 21% since the parent company GSK Plc announced a Rs 6,389-crore open offer on December 16, 2013. Analysts expect the open offer to be successful with the acceptance ratio in the range of 50-80%.
“If Aberdeen, the largest public shareholder in GSK Pharmaceuticals, does not participate in the open offer, the acceptance ratio could be as high as 70%. If they do, number of shares available in the open offer would rise, which would bring down the acceptance ratio to 50%,” said Alok Dalal, vice-president, healthcare, Motilal Oswal Financial Services.
If the open offer meets its target of 24.33% or 2.06 crore shares, the promoters holding would rise from 50.67% to 75%. As per Securities and Exchange Board of India (Sebi) norms, all private sector listed companies need to maintain 25% minimum public shareholding. The public shareholders are allowed to tender their shares between February 7 to 21.
As per market sources, Aberdeen is likely to tender most of its stake as it is facing redemption pressures. Among other institutional shareholders, LIC holds 5.69% or 48 lakh shares. “If LIC does not participate in the offer, the acceptance ratio could be around 57%,” added another analyst with an investment banking firm. “While, if both LIC and Aberdeen stay away from the offer, the ratio could be as high as 80%,” he added. The scrip gained 18.69% on December 16, reacting to the announcement. At R3,100 per share, the offer price was pegged at 26% premium to the then close of R2,468.4. On Friday, the stock closed marginally higher at R2,989.95.
“The attractive pricing should make the offer a success,” says Rahul Sharma, analyst, Karvy Stock Broking. The offer follows the pharma major's announcement it would invest R864 crore in India to set up a factory.